Insider Transactions in Q2 2024 at Ani Pharmaceuticals Inc (ANIP)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 21
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
20,000
-2.85%
|
$1,160,000
$58.9 P/Share
|
|
Jun 20
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
11,447
-1.6%
|
$675,373
$59.86 P/Share
|
|
Jun 18
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
10,607
-1.46%
|
$636,420
$60.76 P/Share
|
|
Jun 17
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
7,946
-1.08%
|
$484,706
$61.41 P/Share
|
|
Jun 13
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.42%
|
$15,750
$63.8 P/Share
|
|
Jun 07
2024
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
11,087
-8.6%
|
$742,829
$67.7 P/Share
|
|
Jun 07
2024
|
James G. Marken SVP OPS & PROD DEV |
BUY
Exercise of conversion of derivative security
|
Direct |
12,550
+4.74%
|
$665,150
$53.29 P/Share
|
|
Jun 05
2024
|
Ori Gutwerg SVP, GENERICS |
SELL
Open market or private sale
|
Direct |
2,985
-3.72%
|
$199,995
$67.0 P/Share
|
|
Jun 04
2024
|
Stephen P. Carey SVP & CFO |
SELL
Open market or private sale
|
Direct |
5,000
-2.99%
|
$315,000
$63.58 P/Share
|
|
Jun 03
2024
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
SELL
Open market or private sale
|
Indirect |
20,000
-8.58%
|
$1,280,000
$64.41 P/Share
|
|
May 21
2024
|
Jeanne Thoma Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,410
+9.8%
|
-
|
|
May 21
2024
|
Patrick D Walsh Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,410
+5.57%
|
-
|
|
May 21
2024
|
Antonio R Pera Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,410
+12.44%
|
-
|
|
May 21
2024
|
Renee P Tannenbaum Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,410
+16.31%
|
-
|
|
May 21
2024
|
Matthew J Leonard Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,410
+26.89%
|
-
|
|
May 21
2024
|
Thomas Haughey Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,410
+7.88%
|
-
|
|
May 21
2024
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Open market or private sale
|
Direct |
2,000
-2.35%
|
$122,000
$61.61 P/Share
|
|
May 20
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
12,855
-1.72%
|
$784,155
$61.81 P/Share
|
|
May 17
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
5,836
-0.78%
|
$361,832
$62.09 P/Share
|
|
May 16
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
16,459
-2.14%
|
$1,036,917
$63.84 P/Share
|
|
May 16
2024
|
Renee P Tannenbaum Director |
SELL
Open market or private sale
|
Direct |
2,000
-9.9%
|
$126,000
$63.87 P/Share
|
|
May 15
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
14,850
-1.9%
|
$965,250
$65.86 P/Share
|
|
May 14
2024
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Open market or private sale
|
Direct |
16,669
-4.23%
|
$1,100,154
$66.1 P/Share
|
|
May 13
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.42%
|
$16,750
$67.69 P/Share
|
|
May 01
2024
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
SELL
Open market or private sale
|
Indirect |
20,000
-7.9%
|
$1,320,000
$66.62 P/Share
|
|
Apr 19
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
16,809
-2.1%
|
$1,092,585
$65.17 P/Share
|
|
Apr 18
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
10,423
-1.29%
|
$667,072
$64.98 P/Share
|
|
Apr 17
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
9,520
-1.16%
|
$618,800
$65.4 P/Share
|
|
Apr 16
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
5,834
-0.71%
|
$385,044
$66.2 P/Share
|
|
Apr 15
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
7,414
-0.89%
|
$489,324
$66.33 P/Share
|
|
Apr 12
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.42%
|
$16,750
$67.79 P/Share
|
|
Apr 10
2024
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,534
-2.64%
|
$299,244
$66.96 P/Share
|
|
Apr 10
2024
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
2,799
-2.36%
|
$184,734
$66.96 P/Share
|
|
Apr 01
2024
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
SELL
Open market or private sale
|
Indirect |
20,000
-7.32%
|
$1,340,000
$67.25 P/Share
|